Xencor, Inc. Profile Avatar - Palmy Investing

Xencor, Inc.

Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that tar…

Biotechnology
US, Monrovia [HQ]

Document Reader

Click To Read:

DEF 14-A Proxies

Not a single DEF 14-A proxy doc.

10-K Filings

Not a single 10-K doc.

10-Q Filings

Not a single 10-Q doc.

LDA 1/2 Filings [Lobbying]

Not a single LDA doc.

End of XNCR's Analysis
CIK: 1326732 CUSIP: 98401F105 ISIN: US98401F1057 LEI: - UEI: -
Secondary Listings
XNCR has no secondary listings inside our databases.